Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers

Abstract

We write this editorial as a cancer survivor (CLB), an oncologist (CLB), and two cancer health services researchers (CLB, JB) in deference to many experts who have formally investigated psychometrics and quality of life (QOL) outcomes among cancer patients who receive erythropoiesis-stimulating agents (ESAs). In this editorial, we report the route by which we have evaluated and continue to consider trade-offs among ESA-treated cancer patients between increased mortality rates, thromboembolic events, transfusions due to chemotherapy-associated anaemia, and QOL. In this journey, we travel behind Brian Leyland-Jones, an oncologist and clinical trialist, who just reported his own personal journey investigating ESAs

Ähnliche Arbeiten